BlackRock’s La Jolla Pharmaceutical Company LJPC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-418,216
| Closed | -$1.33M | – | 6069 |
|
|
2022
Q2 | $1.33M | Sell |
418,216
-8,297
| -2% | -$32.3K | ﹤0.01% | 4418 |
|
|
2022
Q1 | $1.82M | Sell |
426,513
-2,256
| -0.5% | -$9.83K | ﹤0.01% | 4433 |
|
|
2021
Q4 | $1.99M | Buy |
428,769
+3,452
| +0.8% | +$14.4K | ﹤0.01% | 4406 |
|
|
2021
Q3 | $1.7M | Buy |
425,317
+40,622
| +11% | +$161K | ﹤0.01% | 4384 |
|
|
2021
Q2 | $1.65M | Sell |
384,695
-1,114,192
| -74% | -$4.77M | ﹤0.01% | 4355 |
|
|
2021
Q1 | $6.36M | Buy |
1,498,887
+21,388
| +1% | +$118K | ﹤0.01% | 3828 |
|
|
2020
Q4 | $5.73M | Buy |
1,477,499
+36,197
| +3% | +$155K | ﹤0.01% | 3640 |
|
|
2020
Q3 | $5.81M | Sell |
1,441,302
-52,132
| -3% | -$216K | ﹤0.01% | 3507 |
|
|
2020
Q2 | $6.36M | Sell |
1,493,434
-57,920
| -4% | -$353K | ﹤0.01% | 3428 |
|
|
2020
Q1 | $6.52M | Sell |
1,551,354
-22,982
| -1% | -$145K | ﹤0.01% | 3224 |
|
|
2019
Q4 | $6.19M | Buy |
1,574,336
+120,937
| +8% | +$714K | ﹤0.01% | 3443 |
|
|
2019
Q3 | $12.8M | Buy |
1,453,399
+38,634
| +3% | +$365K | ﹤0.01% | 3086 |
|
|
2019
Q2 | $13.1M | Sell |
1,414,765
-30,387
| -2% | -$229K | ﹤0.01% | 3083 |
|
|
2019
Q1 | $9.29M | Sell |
1,445,152
-53,409
| -4% | -$348K | ﹤0.01% | 3157 |
|
|
2018
Q4 | $14.1M | Buy |
1,498,561
+18,557
| +1% | +$279K | ﹤0.01% | 2914 |
|
|
2018
Q3 | $29.8M | Buy |
1,480,004
+25,877
| +2% | +$676K | ﹤0.01% | 2658 |
|
|
2018
Q2 | $42.4M | Buy |
1,454,127
+288,994
| +25% | +$8.92M | ﹤0.01% | 2456 |
|
|
2018
Q1 | $34.7M | Sell |
1,165,133
-12,442
| -1% | -$401K | ﹤0.01% | 2482 |
|
|
2017
Q4 | $37.9M | Buy |
1,177,575
+15,934
| +1% | +$521K | ﹤0.01% | 2441 |
|
|
2017
Q3 | $40.4M | Buy |
1,161,641
+63,602
| +6% | +$2.05M | ﹤0.01% | 2412 |
|
|
2017
Q2 | $32.7M | Buy |
1,098,039
+184,843
| +20% | +$5.3M | ﹤0.01% | 2495 |
|
|
2017
Q1 | $27.3M | Buy |
913,196
+912,107
| +83,756% | +$23.3M | ﹤0.01% | 2574 |
|
|
2016
Q4 | $19K | Sell |
1,089
-130
| -11% | -$2.49K | ﹤0.01% | 3276 |
|
|
2016
Q3 | $29K | Buy |
1,219
+196
| +19% | +$3.69K | ﹤0.01% | 3195 |
|
|
2016
Q2 | $17K | Sell |
1,023
-906
| -47% | -$16.3K | ﹤0.01% | 3318 |
|
|
2016
Q1 | $40K | Buy |
1,929
+1,636
| +558% | +$29.2K | ﹤0.01% | 2495 |
|
|
2015
Q4 | $8K | Sell |
293
-500
| -63% | -$13.6K | ﹤0.01% | 3020 |
|
|
2015
Q3 | $22K | Buy |
793
+500
| +171% | +$15.8K | ﹤0.01% | 2348 |
|
|
2015
Q2 | $7K | Buy |
+293
| New | +$6.04K | ﹤0.01% | 3053 |
|
BlackRock's LJPC Position: Q3 2022 in Review
BlackRock sold out of La Jolla Pharmaceutical Company (LJPC) in Q3 2022, closing a stake of 418,216 shares — an estimated $1.33M sold.
BlackRock first reported a position in LJPC in Q2 2015 and held it in 29 quarters. The position peaked at $42.4M in Q2 2018. 0 funds tracked by Wall St. Rank hold LJPC as of Q3 2022.
- BlackRock reported no remaining La Jolla Pharmaceutical Company position as of Q3 2022 after selling out during the quarter.
- BlackRock sold 418,216 La Jolla Pharmaceutical Company shares in Q3 2022, an estimated $1.33M.
- BlackRock first reported a position in La Jolla Pharmaceutical Company in Q2 2015 and held it in 29 quarters.
- BlackRock's La Jolla Pharmaceutical Company position peaked at $42.4M in Q2 2018.
- 0 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q3 2022.
Based on BlackRock's 13F filing for Q3 2022, filed 14 Nov 2022.